Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer
Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer
复制标题
DOI：
10.1111/j.1365-2354.2012.01336.x
复制
发表时间：
2012-09-01
影响因子：
2.1
通讯作者：
Vilar-Compte, D.
中科院分区：
文献类型：
--
作者：
Cerezo, O.;Onate-Ocana, L. F.;Vilar-Compte, D.
塞雷索岛，奥那特奥卡纳湖F.、ARRIETA-JOFFE P.，冈萨雷斯-拉腊F.，加西亚-帕斯奎尔，巴加洛-罗查河& VILAR-COMPTE D.（2012）European Journal of Cancer Care 21，684-691 Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR 23 questionnaire to assess health-related quality of life in Mexican women with breast cancer本研究的目的是验证墨西哥-西班牙版本的欧洲癌症研究和治疗组织（EORTC）QLQ-BR 23问卷。翻译程序遵循EORTC指南。2009年2月至2010年1月，墨西哥乳腺癌妇女在癌症教学转诊中心完成了QLQ-C30和QLQ-BR 23量表。患者分为两组：（1）早期乳腺癌患者;和（2）局部晚期乳腺癌（LABC）患者。进行了可靠性和有效性测试，并在一组患者中进行了随时间推移的有效性（反应性）。234名女性（平均年龄52.3岁）完成了两份问卷。聚合效度和发散效度都是足够的。除认知和乳腺症状量表（分别为0.52和0.65）外，所有多项量表的Cronbach α值均>= 0.7。与LABC患者（n = 157）相比，早期患者（n = 77）的功能评分更好，症状评分更低。反应性分析后的评分均值变化表明，乳腺癌手术后的变化具有高度敏感性。墨西哥-西班牙语版本的EORTC QLQ-BR 23问卷是评估乳腺癌患者HRQL的有效且合适的工具。
CEREZO O., ONATE-OCANA L. F., ARRIETA-JOFFE P., GONZALEZ-LARA F., GARCIA-PASQUEL M.J., BARGALLO-ROCHA E. & VILAR-COMPTE D. (2012) European Journal of Cancer Care 21, 684-691 Validation of the Mexican-Spanish version of the EORTC QLQ-C30 and BR23 questionnaires to assess health-related quality of life in Mexican women with breast cancer The aim of this study was to validate the Mexican-Spanish version of The European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23 questionnaire. The translation procedure followed EORTC guidelines. QLQ-C30 and QLQ-BR23 instruments were completed by Mexican women with breast cancer, attending a teaching referral cancer centre from February 2009 to January 2010. Patients were divided in two groups: (1) Patients with early stage of breast cancer; and (2) Patients with locally advanced breast cancer (LABC). Reliability and validity tests were performed, and validity over time (responsiveness) was conducted in a subset of patients. Two hundred and thirty-four women (mean age, 52.3 years) completed both questionnaires. Convergent and divergent validity was adequate. Cronbach's alpha of all multi-item scales showed values >= 0.7 except for Cognitive and Breast symptoms scales (0.52 and 0.65 respectively). Patients with early stages (n = 77) showed better functional scores and lower symptoms scores than patients with LABC (n = 157). Score means variation after responsiveness analysis demonstrated high sensitivity to change after breast cancer surgery. The Mexican-Spanish version of the EORTC QLQ-BR23 questionnaire is a valid and suitable instrument to estimate HRQL in patients with breast cancer.